Drug Survival, Safety, and Effectiveness of Biologics in Older Patients with Psoriasis: A Comparison with Younger Patients—A BioCAPTURE Registry Study-Reference-Cited by-同舟云学术

Drug Survival, Safety, and Effectiveness of Biologics in Older Patients with Psoriasis: A Comparison with Younger Patients—A BioCAPTURE Registry Study

Published:2022-07-21 Issue:9 Volume:39 Page:715-727
ISSN:1170-229X
Container-title:Drugs & Aging
language:en
Short-container-title:Drugs Aging

Author:

ter Haar E. L. M.^ORCID,Thomas S. E.^ORCID,van den Reek J. M. P. A.^ORCID,Otero M. E.^ORCID,Njoo M. D.^ORCID,Ossenkoppele P. M.^ORCID,Kop E. N.,Dodemont S. R. P.^ORCID,Körver J. E. M.,Kuijpers A. L. A.^ORCID,Lindhout R. J.,Tupker R. A.^ORCID,Mommers J. M.^ORCID,Berends M. A. M.^ORCID,Koetsier M. I. A.^ORCID,de Bruin-Weller M. S.^ORCID,Visch M. B.^ORCID,Arnold W. P.^ORCID,van Lümig P. P. M.^ORCID,Kleinpenning M. M.,Lubeek S. F. K.^ORCID,de Jong E. M. G. J.^ORCID

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Geriatrics and Gerontology

Link

https://link.springer.com/content/pdf/10.1007/s40266-022-00961-y.pdf

Reference39 articles.

1. Parisi R, Symmons DP, Griffiths CE, Ashcroft DM, Identification, Management of P, et al. Global epidemiology of psoriasis: a systematic review of incidence and prevalence. J Invest Dermatol. 2013;133(2):377–85. https://doi.org/10.1038/jid.2012.339.

2. Michalek IM, Loring B, John SM. A systematic review of worldwide epidemiology of psoriasis. J Eur Acad Dermatol Venereol. 2017;31(2):205–12. https://doi.org/10.1111/jdv.13854.

3. van Winden MEC, van der Schoot LS, van de L’Isle AM, van Vugt LJ, van den Reek J, van de Kerkhof PCM, et al. Effectiveness and safety of systemic therapy for psoriasis in older adults: a systematic review. JAMA Dermatol. 2020;156(11):1229–39. https://doi.org/10.1001/jamadermatol.2020.2311.

4. Schaap MJ, van Winden MEC, Seyger MMB, de Jong EMGJ, Lubeek SFK. Representation of older adults in randomized controlled trials on systemic treatment in plaque psoriasis: a systematic review. J Am Acad Dermatol. 2020;83(2):412–24. https://doi.org/10.1016/j.jaad.2019.07.079.

5. Garcia-Doval I, Carretero G, Vanaclocha F, Ferrandiz C, Dauden E, Sanchez-Carazo JL, et al. Risk of serious adverse events associated with biologic and nonbiologic psoriasis systemic therapy: patients ineligible vs eligible for randomized controlled trials. Arch Dermatol. 2012;148(4):463–70.

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Age affects drug survival rates of interleukin (IL)‐17 and IL‐23 inhibitors in patients with plaque psoriasis: Results from a retrospective, multicentric, multi‐country, cohort study;Journal of the European Academy of Dermatology and Venereology;2024-06-11

2. The implications of exosomes in psoriasis: disease: emerging as new diagnostic markers and therapeutic targets;Molecular Biology Reports;2024-03-29

3. Efficacy and safety of tildrakizumab in elderly patients: real-world multicenter study (ESTER – study);Journal of Dermatological Treatment;2024-02-27

4. Risk of Cutaneous T Cell Lymphoma with Psoriasis Biologic Therapies;Dermatology and Therapy;2023-12-03

5. Comparative Treatment Persistence and Adherence to Endothelin Receptor Antagonists Among Patients with Pulmonary Arterial Hypertension in Japan: A Real-World Administrative Claims Database Study;Pulmonary Therapy;2023-11-22